Atlas Trials

Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)

Clinical trial NCT04267120 · TERMINATED

Trial details

NCT number
NCT04267120
Sponsor
Washington University School of Medicine
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Renal Cell Carcinoma
Start date
2020-07-29
Primary completion
2024-05-09
Enrollment
11

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.